Biogen’s stock hit by soft guidance and a decline in sales of MS drugs

• Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

  Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
  
  CNBC - 18m

• Lyft has ‘no obvious answers’ for its growth woes, as its stock declines

  One issue for Lyft is a downturn in pricing trends, which numerous analysts keyed in on as they looked to make sense of the path forward.
  
  MarketWatch - 33m
• 

  Hampshire owners snap up Southern Brave stake as Hundred sale hits £1bn

  Delhi Capitals co-owners GMR Group secure 49% share Four of the eight franchises will now have IPL backers English cricket has completed arguably its greatest transformation in living memory ...
  
  The Guardian - 3h

• FIS shares plunge most since 2023 on disappointing revenue, guidance miss

  Shares of Fidelity National Information Services had their worst day on the market since 2023 after the company's disappointing guidance.
  
  CNBC - 19h

• Shopify beats on fourth-quarter revenue, but gives mixed guidance

  Shopify said the first quarter is "consistently" its lowest gross merchandise volume quarter seasonally.
  
  CNBC - 19h

• Trump hits pause on blocking a trade loophole. Temu parent’s stock gains.

  The U.S.-listed shares of Temu parent PDD Holdings finished higher Friday after the Trump administration pulled back on its effort to close a so-called de minimis exemption that lets shipments ...
  
  MarketWatch - 4d

• Canopy Growth’s drop in adult-use pot sales snuffs out cannabis-stock momentum

  Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.
  
  MarketWatch - 4d

• Doximity shares pop 36% on revenue beat, rosy guidance

  The company built a digital platform for medical professionals that can help them carry out telehealth appointments with patients, find referrals and more.
  
  CNBC - 4d
• 

  Global chip sales rose 19.1% in 2024 and will hit double digit growth in 2025 thanks to AI | SIA

  Global semiconductor chip sales rose 19.1% to $627.6 billion in 2024 and growth is expected to grow double-digit percentages in 2025.
  
  VentureBeat - 5d

More from MarketWatch

• I’m a wife and mother. Can I secretly change my will and leave everything to my daughter instead of my husband?

  “Happy Valentine’s Day (almost).”
  
  MarketWatch - 24m

• Lyft has ‘no obvious answers’ for its growth woes, as its stock declines

  One issue for Lyft is a downturn in pricing trends, which numerous analysts keyed in on as they looked to make sense of the path forward.
  
  MarketWatch - 33m

• 10-year Treasury yield has biggest one-day jump of 2025 after hot inflation data

  U.S. government debt aggressively sold off on Wednesday, pushing the benchmark 10-year yield up for a fifth straight session, after the consumer-price index for January exceeded expectations and ...
  
  MarketWatch - 42m

• Falling inflation-adjusted yields have cheered investors. Why it may not last.

  The yield on 10-year Treasury inflation-protected securities probably won’t keep falling this year despite its recent retreat, according to Capital Economics.
  
  MarketWatch - 43m

• Three reasons Nvidia’s stock is still compelling, and why it could rise 30% in the next year

  A screen of the S&P 500 still has Nvidia standing out, despite this year’s DeepSeek disruption for the stock.
  
  MarketWatch - 48m

More in Business

• Here's the inflation breakdown for January 2025 — in one chart

  The consumer price index rose 3% on the year in January 2025. Economists worry that broad disinflation is over, even as tariffs loom.
  
  CNBC - 9m

• Bank of America CEO on inflation impact on U.S. economy: ‘Rates are going to stay where they are’

  The Bureau of Labor Statistics reported hotter-than-expected growth in the U.S. consumer price index, forcing markets to recalibrate rate expectations.
  
  CNBC - 13m

• Lyft shares sink 7% on underwhelming fourth-quarter results

  Lyft shares shed about 7% after the ride-sharing app reported lackluster fourth-quarter results and weak bookings guidance due to rising competition.
  
  CNBC - 18m

• Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short

  Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis products.
  
  CNBC - 18m

• Prebiotic soda brand Olipop valued at $1.85 billion in latest funding round

  Olipop's annual sales surpassed $400 million in 2024, as competition heats up with rivals like Poppi.
  
  CNBC - 20m